Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00617071|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : February 15, 2008
Last Update Posted : December 18, 2013
RATIONALE: Developing a personalized screening plan may be more effective than usual care in increasing the number of healthy participants who regularly undergo screening for colorectal cancer.
PURPOSE: This randomized phase III trial is studying personalized screening plans to see how well they work compared with usual care in increasing colorectal cancer screening in healthy participants.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Other: medical chart review Other: survey administration Procedure: fecal occult blood test Procedure: screening colonoscopy||Phase 3|
- To compare the impact of tailored intervention vs standard intervention vs usual care on patient utilization of colorectal cancer (CRC) screening.
- To compare the impact of these interventions on CRC screening preference.
- To compare the impact of these interventions on patient perceptions about CRC screening.
OUTLINE: This is a multicenter study. Participants are stratified by practice and study wave and blocking. Participants are randomized to 1 of 3 arms.
- Arm I (usual care): Participants receive usual care in accordance with their normal patterns of interaction with study practices.
- Arm II (standard intervention [SI]): A generic screening invitation letter, a colorectal cancer (CRC) screening informational booklet, stool blood testing (SBT) cards, and instructions for arranging a colonoscopy screening appointment are mailed to participants on day 15. On day 45, a reminder letter is mailed to participants who have not completed SBT or undergone a screening colonoscopy.
- Arm III (tailored navigation intervention [TNI]): A test-specific screening invitation letter, a CRC screening informational booklet, and additional test-specific materials (i.e., instructions for arranging a colonoscopy screening appointment or SBT cards) are mailed to participants on day 15. On day 30, a patient navigator contacts participants by telephone who have not completed SBT or undergone a screening colonoscopy. The patient navigator re-assesses screening test-specific decision stage; addresses CRC screening barriers; develops a personalized CRC screening plan to move the participant towards screening use (i.e., explains the steps in completing the SBT or scheduling a colonoscopy appointment); and facilitates screening plan implementation. On day 45, a reminder letter is mailed to participants who were contacted by the navigator.
Participants in all arms complete a survey at baseline and then at 6 months. Medical records for each participant are reviewed at 6 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||900 participants|
|Primary Purpose:||Health Services Research|
|Official Title:||Tailored Navigation in CRC Screening|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||December 2010|
- Screening utilization over the 6-month observation period
- Screening preference
- Perceived salience and coherence and self-efficacy related to colorectal cancer (CRC) screening
- Number and length of contacts with each participant and the type of communication during those contacts
- Identification of predictors of CRC screening use and screening preference
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617071
|United States, Pennsylvania|
|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107-5541|
|Contact: Clinical Trials Office - Kimmel Cancer Center at Thomas Jeffer 215-955-6084|
|Study Chair:||Ronald Myers, PhD||Jefferson Medical College of Thomas Jefferson University|